KNTE insider filings
Kinnate Biopharma Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-04-05. Screen KNTE transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for KNTE between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Kinnate Biopharma Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-04-05 | 4 | Farzan Nima — CHIEF EXECUTIVE OFFICER, Director | Disposition to issuer (D): 2,186 · Disposition to issuer (D): 1,281,642 (derivative) · Disposition to issuer (D): 437,413 (derivative) · Disposition to issuer (D): 275,000 (derivative) · Disposition to issuer (D): 400,000 (derivative) · Disposition to issuer (D): 750,000 (derivative) | EDGAR |
| 2024-04-05 | 4 | Krishnamohan Neha — CHIEF FINANCIAL OFFICER | Disposition to issuer (D): 64,087 · Disposition to issuer (D): 270,000 (derivative) · Disposition to issuer (D): 185,000 (derivative) · Disposition to issuer (D): 215,000 (derivative) | EDGAR |
| 2024-04-05 | 4 | Epperly Melissa B, — Director | Disposition to issuer (D): 60,751 (derivative) · Disposition to issuer (D): 20,250 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 20,250 (derivative) | EDGAR |
| 2024-04-05 | 4 | Rome Michael E — Director | Disposition to issuer (D): 40,501 (derivative) · Disposition to issuer (D): 20,250 (derivative) | EDGAR |
| 2024-04-05 | 4 | DeSimone Jill — Director | Disposition to issuer (D): 50,000 (derivative) | EDGAR |
| 2024-04-05 | 4 | Meltz Mark A — COO GENERAL COUNSEL SECRETARY | Disposition to issuer (D): 27,578 · Disposition to issuer (D): 384,508 (derivative) · Disposition to issuer (D): 121,503 (derivative) · Disposition to issuer (D): 100,000 (derivative) · Disposition to issuer (D): 135,000 (derivative) · Disposition to issuer (D): 215,000 (derivative) | EDGAR |
| 2024-04-05 | 4 | Sabzevari Helen — Director | Disposition to issuer (D): 40,501 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 20,250 (derivative) | EDGAR |
| 2024-04-05 | 4 | Foresite Capital Management IV, LLC — 10% owner Foresite Capital Fund IV, L.P. — 10% owner Foresite Capital Management V, LLC — 10% owner Foresite Capital Fund V, L.P. — 10% owner Foresite Capital Opportunity Management V, LLC — 10% owner Foresite Capital Opportunity Fund V, L.P. — 10% owner | Disposition to issuer (D): 9,671,643 · Disposition to issuer (D): 3,525,957 · Disposition to issuer (D): 520,711 | EDGAR |
| 2024-04-05 | 4 | Tananbaum James B. — Director, 10% owner | Disposition to issuer (D): 9,671,643 · Disposition to issuer (D): 3,525,957 · Disposition to issuer (D): 520,711 · Disposition to issuer (D): 40,501 (derivative) · Disposition to issuer (D): 20,250 (derivative) | EDGAR |
| 2024-04-05 | 4 | Smaldone Alsup Laurie — Director | Disposition to issuer (D): 60,751 (derivative) · Disposition to issuer (D): 20,250 (derivative) · Disposition to issuer (D): 20,250 (derivative) · Disposition to issuer (D): 25,000 (derivative) | EDGAR |
| 2024-04-05 | 4 | Flaherty Keith T. — Director | Disposition to issuer (D): 66,377 · Disposition to issuer (D): 32,064 (derivative) · Disposition to issuer (D): 56,112 (derivative) · Disposition to issuer (D): 11,391 (derivative) · Disposition to issuer (D): 20,250 (derivative) · Disposition to issuer (D): 20,250 (derivative) · +1 more | EDGAR |
| 2024-04-05 | 4 | GORDON CARL L — Director, 10% owner | Disposition to issuer (D): 1,368,339 · Disposition to issuer (D): 4,738,453 · Disposition to issuer (D): 1,368,338 · Disposition to issuer (D): 84,599 · Disposition to issuer (D): 450,000 · Disposition to issuer (D): 40,501 (derivative) · +2 more | EDGAR |
| 2024-04-05 | 4 | MITCHELL DEAN J — Director | Disposition to issuer (D): 121,503 (derivative) · Disposition to issuer (D): 20,250 (derivative) · Disposition to issuer (D): 20,250 (derivative) · Disposition to issuer (D): 25,000 (derivative) | EDGAR |
| 2024-04-05 | 4 | ORBIMED ADVISORS LLC — Director, 10% owner OrbiMed Capital GP VII LLC — Director, 10% owner OrbiMed Capital GP VIII LLC — Director, 10% owner OrbiMed Asia GP IV, L.P. — Director, 10% owner OrbiMed Advisors IV Ltd — Director, 10% owner OrbiMed Genesis GP LLC — Director, 10% owner ORBIMED CAPITAL LLC — Director, 10% owner | Disposition to issuer (D): 1,368,339 · Disposition to issuer (D): 4,738,453 · Disposition to issuer (D): 1,368,338 · Disposition to issuer (D): 84,599 · Disposition to issuer (D): 450,000 | EDGAR |
| 2024-03-05 | 4 | Krishnamohan Neha — CHIEF FINANCIAL OFFICER | Tax withholding (F): 1,506 @ $2.59 | EDGAR |
| 2024-03-05 | 4 | Williams Richard Thomas — CHIEF MEDICAL OFFICER | Tax withholding (F): 558 @ $2.59 | EDGAR |
| 2024-03-05 | 4 | Meltz Mark A — COO GENERAL COUNSEL SECRETARY | Tax withholding (F): 558 @ $2.59 | EDGAR |
| 2023-12-05 | 4 | Williams Richard Thomas — Chief Medical Officer | Tax withholding (F): 541 @ $2.25 | EDGAR |
| 2023-12-05 | 4 | Krishnamohan Neha — Chief Financial Officer | Tax withholding (F): 1,459 @ $2.25 | EDGAR |
| 2023-12-05 | 4 | Meltz Mark A — COO General Counsel Secretary | Tax withholding (F): 541 @ $2.25 | EDGAR |
| 2023-09-06 | 4 | Krishnamohan Neha — Chief Financial Officer | Tax withholding (F): 1,459 @ $2.35 | EDGAR |
| 2023-09-06 | 4 | Williams Richard Thomas — Chief Medical Officer | Tax withholding (F): 541 @ $2.35 | EDGAR |
| 2023-09-06 | 4 | Meltz Mark A — COO General Counsel Secretary | Tax withholding (F): 541 @ $2.35 | EDGAR |
| 2023-06-13 | 4 | Epperly Melissa B, — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2023-06-13 | 4 | Sabzevari Helen — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2023-06-13 | 4 | Smaldone Alsup Laurie — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2023-06-13 | 4 | Flaherty Keith T. — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2023-06-13 | 4 | GORDON CARL L — Director, 10% owner | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2023-06-13 | 4 | MITCHELL DEAN J — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2023-06-05 | 4 | Krishnamohan Neha — Chief Financial Officer | Tax withholding (F): 1,459 @ $4.30 | EDGAR |
| 2023-06-05 | 4 | Williams Richard Thomas — Chief Medical Officer | Tax withholding (F): 541 @ $4.30 | EDGAR |
| 2023-06-05 | 4 | Meltz Mark A — COO General Counsel Secretary | Tax withholding (F): 541 @ $4.30 | EDGAR |
| 2023-05-10 | 4 | Foresite Capital Management IV, LLC — 10% owner Foresite Capital Fund IV, L.P. — 10% owner Foresite Capital Fund V, L.P. — 10% owner Foresite Capital Management V, LLC — 10% owner Foresite Capital Opportunity Fund V, L.P. — 10% owner Foresite Capital Opportunity Management V, LLC — 10% owner | Purchase (P): 1,550,956 @ $2.80 · Purchase (P): 229,044 @ $2.80 | EDGAR |
| 2023-05-10 | 4 | Tananbaum James B. — Director, 10% owner | Purchase (P): 1,550,956 @ $2.80 · Purchase (P): 229,044 @ $2.80 | EDGAR |
| 2023-05-08 | 4 | GORDON CARL L — Director, 10% owner | Purchase (P): 83,459 @ $2.75 · Purchase (P): 312,991 @ $2.75 · Purchase (P): 83,459 @ $2.75 · Purchase (P): 490,512 @ $2.82 · Purchase (P): 490,511 @ $2.82 | EDGAR |
| 2023-05-08 | 4 | ORBIMED ADVISORS LLC — Director, 10% owner OrbiMed Capital GP VII LLC — Director, 10% owner OrbiMed Capital GP VIII LLC — Director, 10% owner OrbiMed Asia GP IV, L.P. — Director, 10% owner OrbiMed Advisors IV Ltd — Director, 10% owner OrbiMed Genesis GP LLC — Director, 10% owner ORBIMED CAPITAL LLC — Director, 10% owner | Purchase (P): 83,459 @ $2.75 · Purchase (P): 312,991 @ $2.75 · Purchase (P): 83,459 @ $2.75 · Purchase (P): 490,512 @ $2.82 · Purchase (P): 490,511 @ $2.82 | EDGAR |
| 2023-05-02 | 4 | GORDON CARL L — Director, 10% owner | Purchase (P): 60,998 @ $2.55 · Purchase (P): 228,754 @ $2.55 · Purchase (P): 60,997 @ $2.55 · Purchase (P): 124,544 @ $2.62 · Purchase (P): 467,068 @ $2.62 · Purchase (P): 124,545 @ $2.62 · +3 more | EDGAR |
| 2023-05-02 | 4 | ORBIMED ADVISORS LLC — Director, 10% owner OrbiMed Capital GP VII LLC — Director, 10% owner OrbiMed Capital GP VIII LLC — Director, 10% owner OrbiMed Asia GP IV, L.P. — Director, 10% owner OrbiMed Advisors IV Ltd — Director, 10% owner OrbiMed Genesis GP LLC — Director, 10% owner ORBIMED CAPITAL LLC — Director, 10% owner | Purchase (P): 60,998 @ $2.55 · Purchase (P): 228,754 @ $2.55 · Purchase (P): 60,997 @ $2.55 · Purchase (P): 124,544 @ $2.62 · Purchase (P): 467,068 @ $2.62 · Purchase (P): 124,545 @ $2.62 · +3 more | EDGAR |
| 2023-03-03 | 4 | Williams Richard Thomas — Chief Medical Officer | Tax withholding (F): 638 @ $5.21 | EDGAR |
| 2023-03-03 | 4 | Krishnamohan Neha — Chief Financial Officer | Tax withholding (F): 1,721 @ $5.21 | EDGAR |
| 2023-03-03 | 4 | DeSimone Jill — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2023-03-03 | 4 | Meltz Mark A — COO General Counsel Secretary | Tax withholding (F): 638 @ $5.21 | EDGAR |
| 2023-02-23 | 4 | ORBIMED ADVISORS LLC — Director, 10% owner OrbiMed Capital GP VII LLC — Director, 10% owner OrbiMed Capital GP VIII LLC — Director, 10% owner OrbiMed Asia GP IV, L.P. — Director, 10% owner OrbiMed Advisors IV Ltd — Director, 10% owner OrbiMed Genesis GP LLC — Director, 10% owner ORBIMED CAPITAL LLC — Director, 10% owner | Grant/award (A): 550,000 · Grant/award (A): 550,000 | EDGAR |
| 2023-02-22 | 4 | Foresite Capital Management IV, LLC — 10% owner Foresite Capital Fund IV, L.P. — 10% owner Foresite Capital Fund V, L.P. — 10% owner Foresite Capital Management V, LLC — 10% owner Foresite Capital Opportunity Fund V, L.P. — 10% owner Foresite Capital Opportunity Management V, LLC — 10% owner | Other (J): 1,100,000 | EDGAR |
| 2023-02-22 | 4 | Tananbaum James B. — Director, 10% owner | Other (J): 1,100,000 | EDGAR |
| 2023-02-22 | 4 | GORDON CARL L — Director, 10% owner | Grant/award (A): 550,000 · Grant/award (A): 550,000 | EDGAR |
| 2023-02-15 | 4/A | Farzan Nima — Chief Executive Officer, Director | Grant/award (A): 750,000 (derivative) @ $0 | EDGAR |
| 2023-02-14 | 4 | Williams Richard Thomas — Chief Medical Officer | Grant/award (A): 215,000 (derivative) @ $0 | EDGAR |
| 2023-02-14 | 4 | Farzan Nima — Chief Executive Officer, Director | Grant/award (A): 750,000 (derivative) @ $0 | EDGAR |
| 2023-02-14 | 4 | Meltz Mark A — COO General Counsel Secretary | Grant/award (A): 215,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Kinnate Biopharma Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2024-04-03 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-03-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-02-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-01-16 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-11-22 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2023-11-15 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-11-09 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-09-18 | 8-K | 2.02 — Results of Operations and Financial Condition ? 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-08-08 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-07-28 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=KNTE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs